Drug Discovery Featured Articles & Applications

31. Key Post-Pandemic Trends In Global FDA Observations For Drug Facilities 6/29/2023

    These authors undertook a meticulous analysis of FDA drug facility inspection data spanning from July 2021 through May 2023. The resultant trend insights provide powerful resources for understanding areas of regulatory focus and a benchmark for evaluating potential vulnerabilities.

32. A Brief Overview Of Epigenetics 6/26/2023

    Epigenetics is an emerging domain of scientific research that studies how the environment and behaviors can cause changes that affect the way genes work. This article shares a brief overview of the space.

33. A Brief Introduction To Genome Editing 6/21/2023

    Genome editing technologies enable removal, addition, or alteration of genetic material at particular locations in the genome. This article provides a brief introduction to the space.

34. An Agile Approach To Regulatory Information Management System Transformation 6/20/2023

    Life sciences industry regulators have become increasingly focused on data-driven processes as a means of managing marketing authorization submissions. But this requires that your regulatory information management system (RIMS) upgrades are in a state of continuous evolution and are approached holistically. 

35. The Growing Use Of Antibody Library Technologies In Drug Discovery 6/14/2023

    Antibody library technologies enable the screening and identification of antibodies with desired properties (such as high affinity and specificity) for a wide range of targets, including proteins, peptides, small molecules, and even complex cellular structures. Here are the key emerging trends.

36. FDA Seeks Input On AI Adoption In Drug Development And Manufacture 6/13/2023

    The FDA released two discussion papers for consideration: Using Artificial Intelligence and Machine Learning in the Development of Drug and Biological Products and Artificial Intelligence in Drug Manufacturing. The papers identify current and potential areas for AI adoption.

37. The Global Landscape For Synthetic Biology In Biopharma Through 2035 6/9/2023

    Synthetic biology —  redesigning the genetic material of organisms —  offers a lot of potential with processes like protein engineering and genetic engineering. Using new market research, let's look at emerging trends, market opportunities, regional analysis, and other notable insights.

38. Tapping Into AI/ML Partnerships To Advance Drug Discovery With Recursion Pharma 6/8/2023

    "TechBio" company Recursion Pharma has entered agreements to acquire AI/ML company Cyclica for $40 million and Valence for $47.5 million. To learn about the acquisitions and the future of AI/ML in drug discovery and development, we caught up with Recursion’s CEO Chris Gibson.

39. Targeting Von Willebrand Factor With An RNA Aptamer To Treat Stroke 6/6/2023

    Developing new treatments for acute ischemic stroke that can quickly and safely intervene at the right place and time has been a challenging endeavor. Today, the situation is changing due to technological developments related to stroke and recent advances in RNA-based medicines.

40. Perfused Organ Models: An Alternative To Animal Testing 6/6/2023

    Animal testing has been a long-standing practice in biomedical research, providing valuable insights into disease mechanisms, drug efficacy, and safety. However, ethical concerns, limitations of animal models, and increasing awareness of animal welfare have prompted the development of alternative methods — like perfused organ models (POMs).